In direct compression manufacturing on high-speed rotary presses, compressible pharma-grade sucrose is charged into a 1,000–2,000 L bin blender after geometric pre-blending of active pharmaceutical ingredients below 5.0 wt%. Spray-dried compressible sugar is a co-processed material containing sucrose together with a small fraction of maltodextrin or glucose polymers to stabilize the amorphous state and improve compactibility. The diluent fraction is typically 20.0–60.0 wt% of the finished tablet mass, with microcrystalline cellulose added at 20.0–40.0 wt% to offset the brittle fragmentation tendency of sucrose under main compression. Crospovidone or croscarmellose sodium at 2.0–5.0 wt% provides wicking and rapid disintegration. Blending is performed at 10–12 rpm for 15–20 min; magnesium stearate is added for the final 3–5 min at 0.5–1.0 wt% because the high specific surface area of spray-dried sugar particles can adsorb excessive lubricant and delay tablet disintegration beyond the USP <701> limit. On a 45-station rotary press, precompression force is set between 4.0 kN and 8.0 kN, and main compression force between 12.0 kN and 25.0 kN; turret speed is generally restricted to 35–60 rpm to allow air escape from the sugar matrix. Die fill is controlled by a forced feeder at 20–40 rpm. The compacted sucrose particles undergo plastic deformation and limited brittle fracture; moisture content below 0.3% increases tablet capping on high-speed presses, while moisture above 0.8% causes picking and punch film. Conditioning of the blend at 35–55% RH for 24–72 h before compression stabilizes breaking force. Finished tablets are tested for breaking force according to USP <1217> or Ph. Eur. 2.9.8, with an acceptance range of 50–90 N, and friability is controlled to not more than 1.0% using Ph. Eur. 2.9.7. Disintegration in purified water at 37°C is typically below 15 min when the formulation is optimized; however, higher sucrose fractions above 60 wt% prolong disintegration and require increased disintegrant level or intragranular disintegrant placement.

What Capsule Filling Machine Parameters Are Modified by Sugar Particle Morphology?

Spray-dried compressible sugar particles with a D50 between 150 µm and 250 µm and a Hausner ratio of 1.15–1.25 are suited to tamping-pin capsule fillers operating with five tamping stations and to dosator machines fitted with stainless steel dosator nozzles. The material is qualified by USP <1174> powder flow tests before capsule filling; flow through a 10 mm orifice is typically maintained above 12 g/s. When the sugar content exceeds 40.0 wt% of a capsule blend, tapping station compression thickness is reduced by 0.3–0.5 mm because spray-dried sugar undergoes volume reduction under low force; without this adjustment, capsule plug density increases and disintegration of the finished capsule can exceed 30 min in USP <701> testing. The fill weight target is set at 250–500 mg per capsule, with mass uniformity acceptance of ≤3.5% RSD on a 10-capsule sample as part of USP <905>. Moisture content above 0.8% causes powder adhesion to tamping pins and dosator walls; below 0.3%, electrostatic charging produces variable slug weights, particularly in HPMC capsule shells with low equilibrium moisture. The hopper relative humidity is therefore maintained at 35–55% RH, and the granulation is passed through a 0.5 mm screen immediately before filling to break loose agglomerates. Dosator speed is capped at 40–60 cycles/min for sugar-heavy blends because higher speeds create transient bridging above the nozzle and increase weight variability to 4.0–5.0% RSD. Finished two-piece capsules contain the sugar as a water-soluble filler and binder; dissolution testing is conducted in 900 mL of 0.1 M hydrochloric acid or purified water at 37°C using USP <711> Apparatus 2 at 50 rpm.

Moisture Redistribution in Low-Dose Granule Blends

Wet granulation with compressible sugar in a high-shear mixer proceeds with an impeller tip speed of 2–5 m/s and a chopper speed of 1,500–3,000 rpm. The sugar fraction is 30.0–70.0 wt% of the dry granulate; purified water or starch paste is metered at 10–20% w/w over 3–7 min. Granulation endpoint is determined by power consumption or torque, typically 8–15 N·m at the mixer shaft, rather than by fixed time, because batch-to-batch differences in sugar particle surface moisture alter liquid distribution. Wet mass is passed through a 4.0 mm screen and dried in a fluid-bed dryer with inlet air at 60–80°C, product temperature kept below 45°C, and loss on drying controlled at 1.0–2.5%. The dried granules are milled through a 1.0 mm conical mill or oscillating granulator, and the 150–850 µm fraction is selected for downstream filling. Acidic granulating fluids below pH 4.0 combined with drying temperatures above 50°C can hydrolyze sucrose to glucose and fructose; in formulations containing primary or secondary amine APIs this creates Maillard browning and loss of assay. For such systems the granulating fluid is buffered to pH 5.5–7.0 and drying time is shortened so that product temperature does not exceed 40°C for more than 45 min. The finished granules are used in single-dose sachets or as tableting intermediates; content uniformity after filling is verified by USP <905>, and moisture content is confirmed by USP <921> Karl Fischer titration before final packing.

Freeze-dried parenteral products containing labile proteins, monoclonal antibodies, nucleic acid lipid nanoparticles, or liposomes commonly incorporate injectable-grade sucrose at 5.0–10.0% w/v in the fill solution. Because compressible sugar is a co-processed solid-dosage excipient, parenteral product development instead uses purified injectable-grade sucrose monographed for parenteral administration. The material is dissolved in water for injection, filtered through a 0.2 µm sterilizing-grade polyethersulfone or PVDF membrane, and filled into depyrogenated borosilicate glass vials under Grade A conditions defined by ISO 14644-1 Class 5 and EU GMP Annex 1. Sucrose acts as a cryoprotectant during freezing and as a lyoprotectant during primary drying by replacing water hydrogen bonds at the API surface; for protein formulations the molar ratio of sucrose to protein is frequently in the range of 300:1–500:1. The maximally freeze-concentrated glass transition temperature Tg′ of sucrose-rich solutions is approximately -32°C; primary drying is therefore run with shelf temperature not higher than -25°C and chamber pressure between 6 Pa and 15 Pa to keep product temperature below collapse temperature. Annealing at -15°C to -20°C for 2–4 h is used to complete ice crystal growth and reduce primary drying resistance, but annealing can also promote phase separation in certain polymer-sugar mixtures. Injectable-grade sucrose is controlled for bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14 with a limit below 0.25 EU/mg, for sub-visible particulates by USP <788> Method 1, and for sterility by USP <71> or Ph. Eur. 2.6.1. Terminal steam sterilization of sucrose solutions below pH 5.0 is avoided because heat accelerates hydrolysis to glucose and fructose, changing tonicity contributions and generating reducing sugar degradants. Viscous sucrose solutions above 20% w/v require increased filtration area and a pressure differential not exceeding 1.0–2.0 bar across the membrane. Reconstituted cake appearance is inspected for collapse, shrinkage, and meltback; residual moisture in the lyophilized product is controlled by Karl Fischer titration to not more than 1.0% unless product-specific stability data justify a different limit. Release testing is performed under 21 CFR 211.165.

Thermal and Mechanical Limits of Roller-Compacted Sucrose Granules for Sachet Lines

On continuous sachet packaging lines, the weight control across 10–20 horizontal form-fill-seal filling stations depends on the flow properties of roller-compacted granules containing compressible sugar. Dry granulation is carried out on a roller compactor with roll pressure set between 20 kN and 50 kN, roll speed 5–10 rpm, and screen size 1.0–2.0 mm; the briquettes are milled to a D50 of 300–800 µm. Granules with bulk density 0.60–0.80 g/mL and angle of repose 25–35° feed reliably through auger or vacuum volumetric fillers; lower density leads to head pressure variation in the hopper, and higher density increases filling torque and can stall the auger motor. Magnesium stearate is limited to 0.3–0.5 wt% because sugar granules accumulate hydrophobic lubricant on their surface and the sachet content can become difficult to wet during dissolution testing. Processing suites are maintained at 35–55% RH; below 30% RH, triboelectric charging on polyethylene contact surfaces produces powder segregation and causes fill weight excursions above 5.0% RSD. The sachet structure is usually a three-layer laminate of reverse-printed PET, aluminum foil, and polyethylene; the seal integrity is tested at 150–250 kPa burst pressure or by dye penetration according to internal procedures aligned with pharmacopeial packaging integrity requirements. Finished granules are justified for use by USP <905> content uniformity when the sachet contains a low-dose API below 2.0 mg, and dissolution is assessed in 900 mL purified water at 37°C with USP <711> Apparatus 2 at 50 rpm.

Medicated chewable tablet and lozenge lines that replace cooked candy bases with direct compression technology use compressible sugar as the primary bulking sweetener at 50.0–85.0 wt%. Mannitol or sorbitol is added at 5.0–15.0 wt% to reduce stickiness and provide a cooling mouthfeel, while citric acid or malic acid at 1.0–3.0 wt% adjusts salivary pH and improves flavor release. Compression is performed on a rotary press at 12–25 kN; the resulting chewable tablets show hardness of 80–160 N, friability below 1.0%, and disintegration in simulated saliva at pH 6.8 within 15 min using USP <701>. For lozenges, the sugar fraction can be increased to 85.0–95.0 wt% and compression force to 20–30 kN to create a slowly dissolving compact with hardness above 150 N. High-speed production runs at ambient humidity above 50% RH frequently exhibit sticking to flat-faced or shallow concave punch tips; sodium stearyl fumarate at 0.5–1.5 wt% or a 50:50 mixture with magnesium stearate reduces ejection force and punch filming without the same disintegration delay as an all-magnesium stearate system. The direct compression route eliminates the boiling step required for traditional sugar candy bases, avoiding high-temperature degradation of heat-sensitive actives such as local anesthetics, antihistamines, or probiotics. Finished medicated confections are tested for assay, related substances, dissolution or drug release, and residual moisture; residual moisture is kept at 0.5–1.0% to balance shelf-life firmness against brittle breakage.